All Trials

A Randomized, Multicenter, Open-Label, Phase 2 Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with metastatic or unresectable gastric or GEJ adenocarcinoma that is CAPRIN-1–positive (≥30% cells at ≥2+) after prior therapy, ECOG 0–1, and candidates for ramucirumab/paclitaxel are randomized to ramucirumab/paclitaxel with or without TRK-950. TRK-950 is a humanized IgG1 monoclonal antibody targeting CAPRIN-1 designed to mediate ADCC/ADCP; doses tested are 5 or 10 mg/kg added to standard ramucirumab/paclitaxel.

ClinicalTrials.gov ID: NCT06038578

A Randomized, Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan Versus Trastuzumab, Chemotherapy, and Pembrolizumab for the First Line Treatment of HER2-positive Gastric Cancer (ARTEMIDE-Gastric01)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: First-line trial for adults with unresectable/metastatic HER2-positive, PD-L1 CPS ≥1 gastric/GEJ adenocarcinoma (ECOG 0–1) comparing: (A) rilvegostomig (bispecific PD-1/TIGIT antibody) + fluoropyrimidine + trastuzumab deruxtecan, versus (B) pembrolizumab + trastuzumab + FP or CAPOX, and (C) rilvegostomig + trastuzumab + FP or CAPOX. Key outcomes are PFS/OS; excludes significant autoimmune disease, ILD/pneumonitis risk, uncontrolled HBV/HCV, and LVEF <55%.

ClinicalTrials.gov ID: NCT06764875

STING Agonist and Personalized Ultra-fractionated Stereotactic Adaptive Radiotherapy in Combination With Checkpoint Inhibition for Patients With Metastatic Kidney Cancer (SPARK)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with metastatic clear-cell RCC showing oligoprogression (1–3 lesions) after prior anti–PD-1/CTLA-4 therapy receive continued nivolumab plus PULSAR stereotactic adaptive radiotherapy to all progressing sites, with one lesion also injected intratumorally with the STING agonist IMSA101 (2′3′-cGAMP analog activating TMEM173 to induce type I IFNs) over five doses. Requires at least one safely injectable non-lung lesion; excludes progressive ultracentral/central chest lesions.

ClinicalTrials.gov ID: NCT06601296

A Randomized, Phase 3, Double-blind, Placebo-controlled Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma(RENAVIV)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with unresectable locally advanced or metastatic clear cell RCC, VEGF TKI–naive (allowing ≤1 prior line of cytokine or ICI), are randomized to pazopanib plus the pan–HDAC inhibitor abexinostat versus pazopanib alone. Abexinostat (HDAC class I/II inhibitor that may enhance VEGF-TKI sensitivity via HIF-1α downregulation) is given intermittently with continuous daily pazopanib; crossover to the combination is allowed at progression from the control arm.

ClinicalTrials.gov ID: NCT03592472

Triage of Advanced Cervical Cancer Through Immunotherapy Induction (TRACTION)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Single-arm study for adults with untreated recurrent, persistent, or metastatic cervical cancer (squamous, adeno, or adenosquamous) not amenable to curative therapy, ECOG 0–1, and no prior checkpoint inhibitor or systemic therapy for metastatic disease. Patients receive induction lorigerlimab (MGD019), a bispecific PD-1/CTLA-4 checkpoint inhibitor (DART IgG4) given IV every 3 weeks, with efficacy assessed by RECIST and close safety monitoring for immune-related AEs.

ClinicalTrials.gov ID: NCT05475171

A Biomarker Study of the Wee1 Inhibitor Azenosertib (ZN-c3) in Women With Recurrent or Persistent Uterine Serous Carcinoma

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Single-arm study of azenosertib (ZN‑c3), an oral WEE1 kinase inhibitor that abrogates the G2/M checkpoint and increases replication stress, in adults with recurrent or persistent uterine serous carcinoma after prior platinum therapy (MSI-H/dMMR patients should have received or be ineligible for PD-1/PD-L1 therapy). Requires measurable disease and biopsiable lesion for paired biopsies; assesses antitumor activity and biomarker correlations, with intermittent oral dosing on Days 1–5, 8–12, and 15–19 each cycle.

ClinicalTrials.gov ID: NCT06369155

RESOLVE: letRozole abEmaciclib combinationS in endOmetriaL and oVarian cancEr: A Multi-Cohort Phase 2 Study of Letrozole/Abemaciclib Alone and in Combination With Metformin, Zotatifin and Gedatolisib

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with recurrent/metastatic or treatment‑resistant endometrial cancer (primarily ER+) or low‑grade serous ovarian/fallopian tube/peritoneal carcinoma (ER+ preferred; ER‑ allowed in LGSOC) receive abemaciclib with letrozole, alone or combined with agents targeting PI3K/mTOR/DNA‑PK (samotolisib/LY3023414), pan‑class I PI3K/mTORC1/2 (gedatolisib), translational control via eIF4A (zotatifin), or metabolic/AMPK pathways (metformin). Most cohorts require ECOG 0–1, measurable disease, adequate organ function, and endocrine sensitivity markers; one cohort allows prior CDK4/6 inhibitor exposure.

ClinicalTrials.gov ID: NCT03675893

A Phase 2, Multicenter, Open-label Study of Lifileucel (Tumor-infiltrating Lymphocytes [TIL]) in Participants With Previously Treated Advanced Endometrial Cancer.

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Single-arm study of lifileucel, an autologous tumor-infiltrating lymphocyte (TIL) therapy delivered after lymphodepleting chemotherapy and high‑dose IL‑2, in adults with advanced endometrial carcinoma (including carcinosarcoma) who have progressed after platinum chemotherapy and anti–PD‑1/PD‑L1 therapy, with at least one resectable lesion for TIL manufacture and one measurable lesion. Excludes uterine sarcomas and requires ECOG 0–1 and adequate organ function.

ClinicalTrials.gov ID: NCT06481592

A Phase 2/3 Study of Navtemadlin as Maintenance Therapy in Subjects With TP53WT Advanced or Recurrent Endometrial Cancer Who Responded to Chemotherapy

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with TP53 wild-type advanced or recurrent endometrial cancer who achieved CR/PR after first-line taxane–platinum chemotherapy (ECOG 0–1) are randomized to maintenance navtemadlin vs observation/placebo. Navtemadlin (KRT-232) is an oral MDM2 inhibitor that restores p53 signaling; given Days 1–7 of 28-day cycles, with cytopenias and GI AEs as key class toxicities.

ClinicalTrials.gov ID: NCT05797831

A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Plus Defactinib (FAK Inhibitor) in Recurrent Gynecological Cancers (DURAFAK)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Enrolling adult women with recurrent/progressive gynecologic cancers (e.g., endometrioid, mucinous ovarian, high-grade serous ovarian, others) harboring MAPK-pathway alterations (RAS activation/mutation, BRAF class I–III mutation, and/or NF1 loss), ECOG 0–1, and prior systemic therapy; excludes prior RAF/MEK inhibitor exposure and LGSOC. Treatment is oral avutometinib (dual RAF/MEK “clamp”) plus defactinib (FAK inhibitor).

ClinicalTrials.gov ID: NCT05512208